Note : Speakers and chairs are tentative and pending to be confirmed

 

Thursday, October 1

 

14.00 - 14.15  |  Opening remarks, by Paolo Ghia
14.15 - 15.15  |  Session I. The genesis of CLL

Chairs: Nicholas Chiorazzi, Kostas Stamatopoulos
14.15 - 14.30  |  How many roads to CLL?, by Freda Stevenson
14.30 - 14.45  |  MBL is on the road to CLL: always?, by Lydia Scarfo
14.45 - 15.00  |  CLL-one entity or more? Diagnostic considerations, by Andy Rawstron
15.00 - 15.15  |  Discussion

15.15 - 15.45  |  Break

15.45 - 17.00  |  Session II. Disease trajectories: outcomes, possible explanations and clinical implications

Chairs: Robin Foa, Michael Doubek
15.45 - 16.00  |  Spontaneous regression, by Tanja Stankovic
16.00 - 16.15  |  Clonal evolution: how is it reflected at the genome?, by Cathy Wu
16.15 - 16.30  |  Richter transformation, by Davide Rossi
16.30 - 16.45  |  CHIP and second primary myeloid malignancies, by Panagiotis Baliakas
16.45 - 17.00  |  Discussion

17.00 - 17.30  |  Break

17.30 - 19.00  |  Hands-on workshops | Round 1

Workshop 1. Genomic aberrations
Moderators: Sarka Pospisilova, Richard Rosenquist
Speakers: Eugen Tausch, Sarka Pavlova
17.30 - 18.15  |  Diagnostic aspects and considerations
18.15 - 19.00  |  Clinical interpretation and significance

Workshop 2. Immunogenetics
Moderators: Anastasia Chatzidimitriou, David Oscier
Speakers: Kostas Stamatopoulos, Gianluca Gaidano
17.30 - 18.15  |  Diagnostic aspects and considerations
18.15 - 19.00  |  Clinical interpretation and significance

Workshop 3. MRD
Moderators: Andy Rawstron, Arnon Kater
Speakers: Anton Langerak, Vasiliki Douka
17.30 - 18.15  |  Diagnostic aspects and considerations
18.15 - 19.00  |  Clinical interpretation and significance

Workshop 4. Optimizing clinical outcomes
Moderators: Paolo Ghia, Peter Hillmen
Speakers: Lydia Scarfo, Niki Stavroyianni
17.30 - 18.15  |  Risk-adapted frontline treatment
18.15 - 19.00  |  Sequencing treatment options


Friday, October 2

 

14.30 - 15.45  |  Session III. Proliferation: what lies beneath and how to target it?

Chairs: Silvia Deaglio, Alan Ramsay
14.30 - 14.45  |  CLL and microenvironmental addictions, by Adrian Wiestner
14.45 - 15.00  |  Relevant bystander cells, by Martina Seiffert
15.00 - 15.15  |  Targeting CLL cell proliferation: clinical overview, by Jan Burger
15.15 - 15.45  |  Discussion

15.45 - 16.00  |  Break

16.00 - 17.15  |  Session IV. Resistance to apoptosis

Chairs: Thomas Kipps, Eric Eldering
16.00 - 16.15  |  The anti-apoptotic phenotype: cell-intrinsic drivers, by Stephan Stilgenbauer
16.15 - 16.30  |  The anti-apoptotic phenotype: cell-extrinsic drivers, by Dimitar Efremov
16.30 - 16.45  |  Promoting apoptosis in CLL: clinical overview, by John Seymour
16.45 - 17.15  |  Discussion

17.15 - 17.30  |  Break

17.30 - 19.00  |  Hands-on workshops | Round 2

Workshop 1. Genomic aberrations
Moderators: Sarka Pospisilova, Richard Rosenquist
Speakers: Eugen Tausch, Sarka Pavlova
17.30 - 18.15  |  Diagnostic aspects and considerations
18.15 - 19.00  |  Clinical interpretation and significance

Workshop 2. Immunogenetics
Moderators: Anastasia Chatzidimitriou, David Oscier
Speakers: Kostas Stamatopoulos, Gianluca Gaidano
17.30 - 18.15  |  Diagnostic aspects and considerations
18.15 - 19.00  |  Clinical interpretation and significance

Workshop 3. MRD
Moderators: Andy Rawstron, Arnon Kater
Speakers: Anton Langerak, Vasiliki Douka
17.30 - 18.15  |  Diagnostic aspects and considerations
18.15 - 19.00  |  Clinical interpretation and significance

Workshop 4. Optimizing clinical outcomes
Moderators: Paolo Ghia, Peter Hillmen
Speakers: Lydia Scarfo, Niki Stavroyianni
17.30 - 18.15  |  Risk-adapted frontline treatment
18.15 - 19.00  |  Sequencing treatment options


Saturday, October 3

 

14.30 - 15.45  |  Frontline treatment: state-of-the-art

Chairs: Michael Hallek, John Seymour
Round table discussion
Discussants: Kirsten Fischer, Carol Moreno, Jennifer Woyach, Tait Shanafelt, John Seymour, William Wierda

15.45 - 16.00  |  Break

16.00 - 17.15  |  Management of relapsed/refractory disease: state-of-the-art

Chairs: Peter Hillmen, Jennifer Brown
Round table discussion
Discussants: Barbara Eichhorst, Antonio Cuneo, Arnon Kater, George Follows, Stephen Schuster, Michel van Gelder

17.15 - 17.30  |  Break

17.30 - 18.20  |  Session V. Networking and collaboration – why and how

Chairs: Emili Montserrat, Eva Kimby
17.30 - 17.40  |  US initiatives, by Anthony Mato
17.40 - 17.50  |  The ERIC CLL Database, by Carol Moreno
17.50 - 18.00  |  CLL within HARMONY, by Francesc Bosch
18.00 - 18.10  |  EHA links to EU initiatives and infrastructures, by Ulrich Jaeger
18.10 - 18.20  |  Discussion

18.20 - 18.30  |  Closing remarks, by Paolo Ghia